Compare Amylx Pharmaceuticals Inc (AMLX) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Shell PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Shell PLC trades at $82.3 (market cap $222.30B). The key difference: Shell PLC is far larger — about 112.3× Amylx Pharmaceuticals Inc's market cap, and Shell PLC pays a 3.8% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SHEL | |
|---|---|---|
Market Cap | $1.98B | $222.30B |
Sector | Health | Energy |
52-Week High | $18.70 | $94.15 |
52-Week Low | $7.64 | $70.28 |
Enterprise Value | $1.70B | $274.83B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SHEL trades at $82.23, up 1.02% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.81 and net income margin of 7.01%. Recent Q1 2026 earnings beat expectations, and the company raised its Q2 outlook despite Middle East production disruptions. Analyst consensus is strongly bullish with a $122.20 price target.
The outlook for SHEL is positive, supported by elevated energy prices and strong gas trading, though geopolitical risks and declining operating cash flow pose headwinds. The stock offers value with attractive valuation multiples and a solid dividend, but investors should monitor production volatility and macroeconomic pressures on energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
